Navigation Links
FDA Acting Chief Scientist Ostroff to Speak at the 2014 PDA/FDA Joint Regulatory Conference
Date:7/16/2014

BETHESDA, Md., July 16, 2014 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) has confirmed  FDA's Stephen Ostroff, M.D., Acting Chief Scientist in the Office of the Commissioner will present "FDA's Views on Scientific Advances and their Impact on Manufacturing of the Future" on September 8, 2014 in at the opening plenary session of the 2014 PDA/FDA Joint Regulatory Conference in Washington, DC at the Renaissance Hotel. The Conference dates are September 8-10, 2014, and the theme is "Connecting Regulatory, Quality, Science & Compliance: Assuring Customer-Focused Outcomes throughout the Product Lifecycle"

"Participation of the Agency's Chief Scientist in a session on the future of manufacturing shows that the PDA/FDA Joint Regulatory Conference offers a wider range of information beyond just regulatory information," said PDA President Richard Johnson. "The agenda includes many presentations that are science and technology oriented, with a slant towards the Agency's regulatory role and activities in the various product areas."

Ostroff is responsible for leading and coordinating FDA's cross-cutting scientific and public health efforts. The Office of the Chief Scientist works closely with FDA's product centers, providing strategic leadership and support for FDA's regulatory science and innovation initiatives. 

These initiatives include the Advancing Regulatory Science Initiative, the Critical Path Initiative, scientific professional development, scientific integrity, and the Medical Countermeasure initiative (MCMi).

Ostroff joined FDA in 2013 as Chief Medical Officer in the Center for Food Safety and Applied Nutrition and Senior Public Health Advisor to FDA's Office of Foods and Veterinary Medicine. Prior to that he served as Deputy Director of National Center for Infectious Diseases at the Centers for Disease Control and Prevention (CDC), where he was also Acting Director of CDC's Select Agent Program. He retired from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral (Assistant Surgeon General). 

Ostroff joins 27 other confirmed FDA officials speaking at the conference, including Center for Drug Evaluation and Research Director Janet Woodcock, M.D.

Dr. Janet Woodcock is confirmed to provide remarks addressing "The Cost of Poor Quality" on Tuesday, September 9, 2014

Allergy Laboratories' Susan Schniepp and FDA/Office of Regulatory Affair's (ORA) Monica Caphart are co-chairing this event.  Other confirmed senior FDA officials include: CBER's Dr. Karen Midthun and Mary Malarkey; CVM's Dr. Bernadette Dunham and Dr. Martine Hartogensis; CDER's Ilisa Bernstein; CDRH's Steve Silverman; ORA's Dr. Steven Solomon and Douglas Stearn as well as a host of senior staff scientists and pharmaceutical manufacturing scientists.

To review the entire program and register, please see: http://www.pda.org/global-event-calendar/event-detail/2014-pda-fda-joint-regulatory-conference.

The Conference is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

About PDA – Connecting People, Science and Regulation®

The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 9,500 members worldwide. Go to http://www.pda.org/footer/about-pda to learn more.

Media Inquiries: Walt Morris, 301-656-5900, x. 148; morris@pda.org

Logo - http://photos.prnewswire.com/prnh/20130226/DC66667LOGO


'/>"/>
SOURCE Parenteral Drug Association
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
3. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
4. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
5. Technologies Impacting the Future of Healthcare
6. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
7. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
8. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
9. Polymers in Medical Devices: Opportunities Arising and Trends Impacting the Market
10. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
11. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):